Evaluation and Management of Microscopic Hematuria in Adults ≥ 35 Years

Initial Diagnostic Evaluation

• Microscopic urinalysis confirming ≥ 3 red blood cells per high‑power field is required because dipstick testing alone has a specificity of only 65–99 %. 1
• Examination of urinary sediment for dysmorphic red cells or red‑cell casts indicates a glomerular source and mandates nephrology referral. 1
• Urine culture must be obtained before antibiotics; the presence of pyuria with bacteriuria suggests a urinary‑tract infection. 1
• Baseline serum creatinine should be measured to assess renal function before imaging or contrast administration. 1

Risk Stratification for Urothelial Malignancy

• Age > 35 years confers a 2.6–4 % risk of urologic malignancy in patients with microscopic hematuria. 1
• Active smoking is the strongest modifiable risk factor for urothelial carcinoma. 1
• The combination of microscopic hematuria with pyuria requires differentiation between infection and malignancy. 1

Management of Confirmed Infection

• If the urine culture is positive, initiate antibiotic therapy guided by susceptibility results. 2
• Repeat microscopic urinalysis ≥ 6 weeks after completing antibiotics to determine whether hematuria persists. 1

Upper‑Tract Imaging

• Multiphasic CT urography (CTU)—including unenhanced, nephrographic, and excretory phases with thin‑slice acquisition—is the preferred imaging modality for evaluating the upper urinary tract. 1
• CTU provides superior detection of urolithiasis, renal masses, and urothelial lesions compared with renal ultrasound alone. 1
• When iodinated contrast is contraindicated (e.g., impaired renal function), magnetic‑resonance urography or retrograde pyelography combined with non‑contrast CT should be used. 1
• Renal ultrasound alone is insufficient for a complete hematuria work‑up. 1

Lower‑Tract Evaluation

• White‑light cystoscopy is recommended for all patients ≥ 35 years with persistent microscopic hematuria to directly visualize the bladder and urethra. 1
• Flexible cystoscopy offers diagnostic accuracy comparable to rigid cystoscopy while providing better patient tolerance. 3
• Most cancers identified in hematuria patients are bladder cancers, which are optimally detected by direct cystoscopic visualization. 1

Laboratory Adjuncts

• Urine cytology is not routinely recommended for the initial evaluation of microscopic hematuria. 1
• Cytology may be considered in smokers or patients with irritative voiding symptoms because of the higher risk of carcinoma in situ. 1

BPH‑Related Considerations

• 5‑alpha reductase inhibitors (finasteride or dutasteride) can reduce prostatic vascularity and control hematuria in BPH patients with prostate volume > 30 mL; full effect may take up to one year, with additional benefits of prostate‑size reduction, lower acute‑retention risk, and decreased need for surgery. 5
• Alpha‑blockers improve lower‑urinary‑tract symptoms rapidly but do not prevent disease progression or reduce hematuria. 3

Prostate Assessment

• A digital rectal examination should be performed as part of BPH assessment; a palpable nodule or induration requires further prostate‑cancer evaluation. 4
• PSA measurement may aid BPH treatment decisions, but shared decision‑making is essential because of implications for prostate‑cancer screening. 3

Indications for Nephrology Referral

• Proteinuria ≥ 2 + on dipstick or ≥ 1 g/24 h on quantitative testing. 1
• Dysmorphic red cells > 80 % of urinary RBCs or presence of red‑cell casts. 1
• Elevated or rising serum creatinine. 1
• Hypertension occurring in the setting of hematuria. 1

Follow‑Up Strategy

• Repeat microscopic urinalysis at 6, 12, 24, and 36 months when the initial work‑up is negative. 1
• Blood‑pressure monitoring at each follow‑up visit. 1
• Immediate re‑evaluation is required if any of the following occur: gross hematuria, microscopic hematuria > 25 RBC/HPF, or new irritative voiding symptoms without evidence of infection. 1

Critical Pitfalls to Avoid

• Do not attribute hematuria solely to BPH without completing age‑appropriate malignancy screening, especially in smokers. 1
• Do not rely on dipstick testing alone; microscopic confirmation is mandatory. 1
• Anticoagulation is not an excuse to skip a comprehensive hematuria work‑up. 1
• Renal ultrasound should not be used as the sole imaging modality for hematuria evaluation. 1